Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients with Cardiogenic Shock from Acute Myocardial Infarction - NORshock

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510892-40-00

Acronym

NL79416.018.21

Enrollment

918

Registered

2024-02-19

Start date

2024-02-29

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction complicated by cardiogenic shock

Brief summary

The primary endpoint of the study is the composite of all-cause mortality and severe renal failure requiring renal replacement therapy within 30 days after randomization.

Detailed description

All-cause mortality at 30 days, Days alive and out of hospital (30 days)

Interventions

DRUGNOREPINEPHRINE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint of the study is the composite of all-cause mortality and severe renal failure requiring renal replacement therapy within 30 days after randomization.	—

Secondary

Measure	Time frame
All-cause mortality at 30 days, Days alive and out of hospital (30 days)	—

Countries

Belgium, Czechia, Denmark, Germany, Greece, Netherlands, Norway, Slovenia, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026